1. Home
  2. Detail

@b.weave: This just in: millennial buys physical media #hazbinhotel #vinyl #vizziepop #fyp #fypツ #foryoupage #foryou #fypage #foryou #xybca #trending

b.weave
b.weave
Open In TikTok:
Region: US
Wednesday 24 July 2024 21:31:23 GMT
440
32
0
1

Music

Download

No Watermark .mp4 (0.37MB) No Watermark(HD) .mp4 (0.37MB) Watermark .mp4 (0.41MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @b.weave, please go to the Tikwm homepage.

Other Videos

🐈🦆#miaw #kucinglucu #bebek #fyp
🐈🦆#miaw #kucinglucu #bebek #fyp
⭐️ The DESTINY-Breast 06 trial was presented at ASCO this weekend and looks at Enhertu for HR+/HER2 low or ultralow metastatic breast cancer. This study is important for 2 reasons: 1. It included patients w HER2 ultralow (essentially any amount of HER2 expression that’s not zero but not enough to be low) which creates a new category and may offer more treatment options to more patients. Previously, these patients would have been considered HER2 negative and not been eligible for Enhertu. We will have to go back and look at HER2 negative patients to see if they are HER2 ultra low. 2. Currently, Enhertu is given in this population after disease progression on endocrine therapy, and at least one line of chemotherapy. In the study, Enhertu was moved up in the treatment paradigm. After progression on endocrine therapy, patients were randomized to Enhertu or chemotherapy. Patients receiving #enhertu a 37% reduction in risk of progression or death, which translated to a 5.1 month improvement. Patients receiving chemo had an average progression free survival (alive without progression) of 8.1 months compared to 13.2 months in patients receiving Enhertu. 👏👏 Enhertu did have some more side effects and does have a 11% incidence of interstitial lung disease/pneumonitis 🫁 so we definitely have to watch for that. 🚨 Not yet FDA approved to be given in ultra low or before chemo but very important data and will see what happens w FDA approvals! Let me know your questions. ##asco24##her2##her2low##metastaticbreastcancer##stageivcancer##mbc##oncologist##cancerdoctor
⭐️ The DESTINY-Breast 06 trial was presented at ASCO this weekend and looks at Enhertu for HR+/HER2 low or ultralow metastatic breast cancer. This study is important for 2 reasons: 1. It included patients w HER2 ultralow (essentially any amount of HER2 expression that’s not zero but not enough to be low) which creates a new category and may offer more treatment options to more patients. Previously, these patients would have been considered HER2 negative and not been eligible for Enhertu. We will have to go back and look at HER2 negative patients to see if they are HER2 ultra low. 2. Currently, Enhertu is given in this population after disease progression on endocrine therapy, and at least one line of chemotherapy. In the study, Enhertu was moved up in the treatment paradigm. After progression on endocrine therapy, patients were randomized to Enhertu or chemotherapy. Patients receiving #enhertu a 37% reduction in risk of progression or death, which translated to a 5.1 month improvement. Patients receiving chemo had an average progression free survival (alive without progression) of 8.1 months compared to 13.2 months in patients receiving Enhertu. 👏👏 Enhertu did have some more side effects and does have a 11% incidence of interstitial lung disease/pneumonitis 🫁 so we definitely have to watch for that. 🚨 Not yet FDA approved to be given in ultra low or before chemo but very important data and will see what happens w FDA approvals! Let me know your questions. ##asco24##her2##her2low##metastaticbreastcancer##stageivcancer##mbc##oncologist##cancerdoctor
The secret of the sea #sea
The secret of the sea #sea
أول مرة في حياتي بعيش حياتي أنا من جديد❤️🎶🎶#موسيقى
أول مرة في حياتي بعيش حياتي أنا من جديد❤️🎶🎶#موسيقى


Simpan jadi kenangan ❤️ #rayavibe
Simpan jadi kenangan ❤️ #rayavibe

About

Legal